APL 030
Alternative Names: APL-030Latest Information Update: 15 Jul 2024
At a glance
- Originator Apollo Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action EIF2AK4 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Acute myeloid leukaemia
Most Recent Events
- 25 Jun 2024 Preclinical trials in Acute myeloid leukaemia in United Kingdom (PO)
- 05 Apr 2024 Pharmacodynamics data from preclinical studies in Acute myeloid leukaemia presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 05 Apr 2024 Apollo Therapeutics plans a phase I/II trial in Haematological malignancies